** Shares of drug developer INmune Bio INMB.O rise 7% to $2.74 in early trade

** Co says its therapy for a type of prostate cancer has met the main and secondary goals of an early-to-mid-stage study

** INMB says the therapy, INKmune, "was well tolerated at all three dose levels in the trial, demonstrating an excellent safety profile," which was the main goal of the trial

** As a result, co stops further enrollment into the study

** Including session's moves, stock down 41.3% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))